News
TERN
52.95
0.00%
0.00
'Merck Starts Seven-Part High-Grade Bond Sale to Fund Terns Deal' - Bloomberg
Benzinga · 05/18 13:07
Terns Pharmaceuticals Delists Following Merck Acquisition Completion
TipRanks · 05/05 13:49
*Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK
Dow Jones · 05/05 12:48
*Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK
Dow Jones · 05/05 12:48
*Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK
Dow Jones · 05/05 12:47
Merck completes acquisition of Terns Pharmaceuticals for $53 a share
PUBT · 05/05 12:45
MERCK COMPLETES ACQUISITION OF TERNS PHARMACEUTICALS, INC.
Reuters · 05/05 12:45
Press Release: Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Dow Jones · 05/05 12:45
NASDAQ TRADE HALT <TERN.O> REASON NOT AVAILABLE AT 03:58 AM
Reuters · 05/05 07:58
Weekly Report: what happened at TERN last week (0427-0501)?
Weekly Report · 05/04 09:43
Do Wall Street Analysts Like Merck & Co. Stock?
Barchart · 05/04 03:27
Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
Seeking Alpha · 05/03 13:35
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
TipRanks · 04/30 19:32
Merck's Q1 adjusted loss less than expected despite Cidara acquisition charge
Reuters · 04/30 11:03
Terns Pharmaceuticals Cut to Perform From Outperform by Oppenheimer
Dow Jones · 04/27 14:11
Oppenheimer Downgrades Terns Pharmaceuticals to Perform, Removes Price Target $58
Benzinga · 04/27 14:00
Terns Pharmaceuticals granted breakthrough therapy designation for TERN-701
TipRanks · 04/27 13:01
Terns Pharmaceuticals Gets Breakthrough Designation for Leukemia Treatment
Dow Jones · 04/27 12:41
Merck: Bullish Setup Into Q1 Earnings
Seeking Alpha · 04/27 12:39
Terns Pharmaceuticals Gains FDA Breakthrough Status for TERN-701
TipRanks · 04/27 12:30
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.